Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, HARVARD BIOSCIENCE, INC. reported revenue of $87M, down 8.1% year over year. Operating margin was -56.1% and net margin -65.5%, on a free-cash-flow margin of 6.3% with capital expenditure at 1.5% of revenue. Every figure is computed directly from HBIO's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $87M | -56.1% | -65.5% |
| FY2024 | $94M | -6.6% | -13.2% |
| FY2023 | $112M | 1.7% | -3.0% |
| FY2022 | $113M | -6.1% | -8.4% |
| FY2021 | $119M | 1.7% | -0.2% |
How does HBIO compare against its actual peer set?
The full CompsDesk Peer Benchmark Pack: up to 14 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, provenance for every number, board-ready PDF + CSV. One-off $249.
Related in the same sector: A · AEHR · AERG · AEVA · AIRI · ALGN
See HBIO benchmarked against two sector peers (free) →
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.